Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Immunosuppressive entities in the tumor microenvironment (TME) remain a major impediment to immunotherapeutic approaches for a majority of patients with cancer. While the immunosuppressive role of transforming growth factor-β (TGF-β) in the TME is well known, clinical studies to date with anti-TGF-β...

Descripción completa

Detalles Bibliográficos
Autores principales: Lind, Hanne, Gameiro, Sofia R, Jochems, Caroline, Donahue, Renee N., Strauss, Julius, Gulley, James L, Palena, Claudia, Schlom, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057416/
https://www.ncbi.nlm.nih.gov/pubmed/32079617
http://dx.doi.org/10.1136/jitc-2019-000433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057416/
https://www.ncbi.nlm.nih.gov/pubmed/32079617
http://dx.doi.org/10.1136/jitc-2019-000433

Ejemplares similares